CA2556805C - Use of factor xiii for stimulating the perfusion of ischemic tissue - Google Patents

Use of factor xiii for stimulating the perfusion of ischemic tissue Download PDF

Info

Publication number
CA2556805C
CA2556805C CA2556805A CA2556805A CA2556805C CA 2556805 C CA2556805 C CA 2556805C CA 2556805 A CA2556805 A CA 2556805A CA 2556805 A CA2556805 A CA 2556805A CA 2556805 C CA2556805 C CA 2556805C
Authority
CA
Canada
Prior art keywords
fxiii
fxllla
factor xiii
perfusion
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2556805A
Other languages
English (en)
French (fr)
Other versions
CA2556805A1 (en
Inventor
Aida Inbal
Rima Dardik
Jonathan Leor
Gerhard Dickneite
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring GmbH Deutschland
Original Assignee
CSL Behring GmbH Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Behring GmbH Deutschland filed Critical CSL Behring GmbH Deutschland
Publication of CA2556805A1 publication Critical patent/CA2556805A1/en
Application granted granted Critical
Publication of CA2556805C publication Critical patent/CA2556805C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
CA2556805A 2004-02-20 2005-02-15 Use of factor xiii for stimulating the perfusion of ischemic tissue Expired - Fee Related CA2556805C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04003950.5 2004-02-20
EP04003950A EP1566183A1 (en) 2004-02-20 2004-02-20 Use of factor XIII for stimulating the perfusion of ischemic tissue
PCT/EP2005/001495 WO2005079839A1 (en) 2004-02-20 2005-02-15 Use of factor xiii for stimulating the perfusion of ischemic tissue

Publications (2)

Publication Number Publication Date
CA2556805A1 CA2556805A1 (en) 2005-09-01
CA2556805C true CA2556805C (en) 2013-04-02

Family

ID=34707356

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2556805A Expired - Fee Related CA2556805C (en) 2004-02-20 2005-02-15 Use of factor xiii for stimulating the perfusion of ischemic tissue

Country Status (11)

Country Link
US (1) US20070167361A1 (https=)
EP (2) EP1566183A1 (https=)
JP (1) JP2007523111A (https=)
KR (1) KR20060123567A (https=)
AT (1) ATE429244T1 (https=)
AU (1) AU2005215114B2 (https=)
CA (1) CA2556805C (https=)
DE (1) DE602005014085D1 (https=)
DK (1) DK1718328T3 (https=)
ES (1) ES2325996T3 (https=)
WO (1) WO2005079839A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITTO20130532A1 (it) * 2013-06-27 2014-12-28 Donato Gemmati Nuovo biomarcatore prognostico nell'infarto acuto del miocardio

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69431430T2 (de) * 1993-03-30 2003-05-22 Hoechst Japan Ltd., Tokio/Tokyo Faktor XIII zur Behandlung von Hautwunden
AU7483798A (en) * 1997-05-14 1998-12-08 Zymogenetics Inc. Use of factor xiii for the manufacture of a medicament for the treatment of reperfusion injury and mucosal damage
EP1572168B1 (en) * 2002-02-06 2010-05-26 Vicor Technologies, Inc. Anti-infarction molecules

Also Published As

Publication number Publication date
ATE429244T1 (de) 2009-05-15
KR20060123567A (ko) 2006-12-01
EP1718328A1 (en) 2006-11-08
AU2005215114B2 (en) 2010-05-20
EP1566183A1 (en) 2005-08-24
DK1718328T3 (da) 2009-07-27
WO2005079839A1 (en) 2005-09-01
DE602005014085D1 (de) 2009-06-04
US20070167361A1 (en) 2007-07-19
EP1718328B1 (en) 2009-04-22
ES2325996T3 (es) 2009-09-28
JP2007523111A (ja) 2007-08-16
AU2005215114A1 (en) 2005-09-01
CA2556805A1 (en) 2005-09-01

Similar Documents

Publication Publication Date Title
FI104790B (fi) Menetelmä aktivoidun proteiini C:n valmistamiseksi
US8377881B2 (en) Compositions and methods for reducing scar formation in wound healing
US6825323B2 (en) Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
Kwaan et al. Fibrinolytic activity in thrombosed veins
FI85334C (fi) Foerfarande foer framstaellning av en vattenbaserad, vaevnadsplasminogenaktivator (t-pa) innehaollande, koncentrerad parenterad loesning.
FI85335B (fi) Foerfarande foer framstaellning av lyofiliserad, farmaceutisk vaevnadsplasminogenaktivator(t-pa)-komposition.
AU2003255290A1 (en) Use of erythropoietin
TW200829267A (en) Method of treating endothelial dysfunction
US5364622A (en) Methods for preventing adhesions to organs and parts of organs by application of tissue plasminogen activator and hydroxyethylcellulose hydrogel
JP2003500364A (ja) フィブリノーゲン、トロンビン、トランスグルタミナーゼ及びプロテイナーゼインヒビターを含有する局所投与のための薬剤
ES2251953T3 (es) Uso de desmopresina en la preparacion de un medicamento inhibidor de la diseminacion metastasica durante la cirugia del cancer.
Dewar et al. Fibrinolytic therapy of coronary thrombosis
CA2556805C (en) Use of factor xiii for stimulating the perfusion of ischemic tissue
EP0914830A1 (en) Neovascularization inhibitor containing tissue factor pathway inhibitor
Kwaan et al. Localization of fibrinolytic activity in myocardial infarcts in rats
Jin et al. Central zone of myocardial infarction: a neglected target area for heart cell therapy
ES2263582T3 (es) Utilizacion del factor de crecimiento para prevenir o tratar cardiopatias isquemicas o accidentes cardiovasculares.
US8263756B2 (en) Method of gene transfer via vascular system or ureter
EP0669834A1 (en) Use of topically applied factor xiii for inhibiting hemorrhage
AU2001227771B2 (en) Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen
US20250295741A1 (en) Prevention of post-operative atrial fibrillation with a botulinum toxin
CA1319610C (en) Method for inducing endogenous production of tissue plasminogen activator (tpa)
CN119454907A (zh) Vegf-c156s在制备减轻静脉移植物狭窄的药物中的应用
Liu Engineering Fibrin Biomaterials with α2-Antiplasmin and Growth Factors in Regenerative Medicine
JPH08268910A (ja) プロテインｃの皮下投与のための薬剤

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20180215